U.S. markets closed
  • S&P 500

    3,465.39
    +11.90 (+0.34%)
     
  • Dow 30

    28,335.57
    -28.09 (-0.10%)
     
  • Nasdaq

    11,548.28
    +42.28 (+0.37%)
     
  • Russell 2000

    1,640.50
    +10.25 (+0.63%)
     
  • Crude Oil

    39.78
    -0.86 (-2.12%)
     
  • Gold

    1,903.40
    -1.20 (-0.06%)
     
  • Silver

    24.70
    -0.01 (-0.04%)
     
  • EUR/USD

    1.1868
    +0.0042 (+0.36%)
     
  • 10-Yr Bond

    0.8410
    -0.0070 (-0.83%)
     
  • GBP/USD

    1.3038
    -0.0042 (-0.32%)
     
  • USD/JPY

    104.6900
    -0.1500 (-0.14%)
     
  • BTC-USD

    12,899.83
    -5.16 (-0.04%)
     
  • CMC Crypto 200

    259.33
    -2.12 (-0.81%)
     
  • FTSE 100

    5,860.28
    +74.63 (+1.29%)
     
  • Nikkei 225

    23,516.59
    +42.32 (+0.18%)
     

MERGER ALERT - WTRE, BBIO, and LSAC: Levi & Korsinsky, LLP Reminds Investors of Investigations Concerning the Mergers of these Companies

·2 mins read

NEW YORK, NY / ACCESSWIRE / October 16, 2020 / The following statement is being issued by Levi & Korsinsky, LLP:

Levi & Korsinsky, LLP announces that investigations have commenced on behalf of shareholders of the following publicly-traded companies.


Watford Holdings Ltd. (NASDAQ:WTRE)
Merger Announcement: October 9, 2020
Transaction Details: Under the terms of the deal, Watford Holdings shareholders will receive $31.10 in cash for each Watford Holdings common share they hold.

To learn more about the WTRE investigation and your rights, go to:
https://www.zlk.com/mna2/watford-holdings-ltd-information-request-form

BridgeBio Pharma, Inc. (NASDAQ:BBIO)
Merger Announcement: October 5, 2020
Transaction Details: Under the terms of the merger, BridgeBio has agreed to acquire all of the outstanding common stock of Eidos it does not already own, representing approximately 36.3% of Eidos' outstanding shares. Eidos stockholders will have the right to receive in the transaction, at their election, either 1.85 shares of BridgeBio common stock or $73.26 in cash per Eidos share in the transaction.

To learn more about the BBIO investigation and your rights, go to:
https://www.zlk.com/mna2/bridgebio-pharma-inc-information-request-form


LifeSci Acquisition Corp. (NASDAQ:LSAC)
Merger Announcement: September 29, 2020
Transaction Details: The terms of the merger, current stockholders of Vincera will own approximately 40% of the combined company.

To learn more about the LSAC investigation and your rights, go to:
https://www.zlk.com/mna2/lifesci-acquisition-corp-information-request-form

Levi & Korsinsky is a nationally recognized firm with offices in New York, Connecticut, California, and Washington, D.C. The firm's attorneys have extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities lawsuits, and have recovered hundreds of millions of dollars for aggrieved shareholders. For more information, please feel free to contact any of the attorneys listed below. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
jlevi@levikorsinsky.com
55 Broadway, 10th Floor
New York, NY 10006
Tel: (212) 363-7500
Fax: (212) 363-7171
www.zlk.com

SOURCE: Levi & Korsinsky, LLP



View source version on accesswire.com:
https://www.accesswire.com/610860/MERGER-ALERT--WTRE-BBIO-and-LSAC-Levi-Korsinsky-LLP-Reminds-Investors-of-Investigations-Concerning-the-Mergers-of-these-Companies